E. De Maio

发表

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

N. Normanno, G. de Feo, J. Bryce, 2009, The oncologist.

Statistical design in phase II clinical trials and its application in breast cancer.

G. Signoriello, G. Di Lorenzo, M. Di Maio, 2003, The Lancet. Oncology.

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

G. Botti, N. Normanno, G. de Feo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Is human hepatocellular carcinoma a hormone-responsive tumor?

S. Pignata, B. Daniele, M. Di Maio, 2008, World journal of gastroenterology.

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.

G. D'aiuto, G. Botti, G. de Feo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.

M. Rinaldo, G. D'aiuto, G. Botti, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

G. D'aiuto, G. Botti, N. Normanno, 2006, British Journal of Cancer.

Should Adjuvant Chemotherapy be used to Treat Breast Cancer in Elderly Patients (≥ 70 Years of Age)? Pro

F. Perrone, E. De Maio, 2002, Tumori.

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

L. Livi, M. Scalese, M. Pistelli, 2022, npj Breast Cancer.

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

M. Rinaldo, G. D'aiuto, C. Pacilio, 2005, BMC Cancer.

The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.

C. Gridelli, G. Signoriello, A. Morabito, 2008, Lung cancer.

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

G. D'aiuto, G. Botti, F. Nuzzo, 2002, Cancer.

Methodology of clinical trials with new molecular-targeted agents: where do we stand?

N. Normanno, F. Perrone, M. Di Maio, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents

S. Pignata, M. Di Maio, E. De Maio, 2002, Tumori.

Hepatocellular Carcinoma: Systemic Treatments

S. Pignata, B. Daniele, M. Di Maio, 2002, Journal of clinical gastroenterology.

Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?

C. Gridelli, N. Normanno, A. De Luca, 2004, Anticancer research.

Hormonal Treatment of Human Hepatocellular Carcinoma

M. Di Maio, C. Gallo, A. Morabito, 2006, Annals of the New York Academy of Sciences.

First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients: A Phase II Study

A. Rossi, S. Pignata, B. Daniele, 2003, Journal of clinical gastroenterology.

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

S. Barni, G. Botti, G. Botti, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

G. D'aiuto, G. Signoriello, C. Pacilio, 2008, Critical reviews in oncology/hematology.

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

A. Giordano, N. Normanno, A. De Luca, 2005, Endocrine-related cancer.

Consequences of targeted treatments for second-line therapy.

L. Landi, C. Tibaldi, A. D’Incecco, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

N. Normanno, M. Di Maio, A. Morabito, 2006, The oncologist.

Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP).

F. Izzo, S. Pignata, B. Daniele, 2006, Critical reviews in oncology/hematology.

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

S. Barni, N. Normanno, C. Pacilio, 2019, European journal of cancer.

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

S. Barni, R. Labianca, G. Luporini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial

A. Vecchione, A. Rossi, C. Gridelli, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

M. Rinaldo, G. D'aiuto, G. Botti, 2011, BMC Cancer.

Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer.

G. Di Lorenzo, M. Di Maio, C. Gallo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature.

F. Fiore, S. Pignata, B. Daniele, 2003, Critical reviews in oncology/hematology.

Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

S. Pignata, B. Daniele, G. Signoriello, 2006, BMC Cancer.

Supportive care in patients with advanced non-small-cell lung cancer

C. Gridelli, L. Frontini, F. Perrone, 2003, British Journal of Cancer.

Methodological aspects of lung cancer clinical trials in the era of targeted agents.

C. Gridelli, M. Di Maio, C. Gallo, 2010, Lung cancer.

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

G. D'aiuto, G. Botti, G. Signoriello, 2007, BMC Cancer.

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

G. Botti, N. Normanno, G. Esposito, 2012 .

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.

M. Emdin, M. Scalese, G. Bocci, 2023, Clinical and Experimental Medicine (Testo stampato).

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.

G. D'aiuto, G. Botti, G. Esposito, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.